Table 1.
Clinical details and FOXL2 C134W mutation status for GCT, cell lines, and normal ovarian tissue samples
| Sample | Tissue type | FOXL2 C134W status | Age (years) | Menopausal status | Tumor stage |
|---|---|---|---|---|---|
| 1 | Adult GCT | Het | 31 | Pre | I |
| 2 | Adult GCT | Het | 43 | Pre | Ia |
| 3 | Adult GCT | Het | 53 | Pre | I |
| 4 | Adult GCT | Het | 54 | Pre | I |
| 5 | Adult GCT | Het | 50 | Post | Ic |
| 6 | Adult GCT | Het | N/A | N/A | N/A |
| 7 | Adult GCT | Het | 48 | Pre | Recurrent |
| 8 | Adult GCT | Het | 85 | Post | Recurrent |
| 9 | Adult GCT | Het | 66 | Post | Recurrent, metastatic |
| 10 | Adult GCT | Het | 58 | Post | Recurrent |
| 11 | Adult GCT | Hemi/Homozygous | 50 | Pre | Recurrent |
| 12 | Adult GCT | Het | 45 | Pre | Recurrent |
| 13 | Adult GCT | Het | 56 | Post | Recurrent |
| 14 | Juvenile GCT | WT | 4 | Pre | Juvenile |
| 15 | Juvenile GCT | WT | 17 | Pre | Juvenile, (metastatic?) II |
| 16 | Juvenile GCT | WT | ∼33 | Pre | Juvenile, recurrent |
| KGN | Cell line | Het | 73 | – | Recurrent |
| COV434 | Cell line | WT | 27 | – | Primary—metastatic |
| 17 | Normal ovary | WT | N/A | Pre | N/A |
| 18 | Normal ovary | WT | N/A | Pre | N/A |
| 19 | Normal ovary | WT | 41 | Pre | Endometriosis/adenomyosis |
| 20 | Normal ovary | WT | 43 | Pre | Cervical adenoma |
| 21 | Normal ovary | WT | 49 | Pre | Fibroid uterus |
| 22 | Normal ovary | WT | 33 | Pre | Intractable premenstrual tension |
| 23 | Normal ovary | WT | 30 | Pre | Endometrial carcinoma |
| 24 | Normal ovary | WT | 50 | Pre | Endometrial carcinoma |
| 25 | Normal ovary | WT | 48 | Pre | Endometriosis/adenomyosis |
| 26 | Normal ovary | WT | 48 | Pre | N/A |
Normal ovaries are from patients who have undergone total abdominal hysterectomy/bilateral salpingo-oophorectomy for the following conditions: endometriosis/adenomyosis (nos. 19 and 25), endometrial carcinoma (nos. 23 and 24), fibroid uterus (no. 21), cervical adenoma (no. 20), and intractable premenstrual tension (no. 22)